title: Long course and prognostic factors of virus-induced cirrhosis of the liver.
abstract: OBJECTIVE
  Chronic infection by hepatitis B virus (HBV) and hepatitis C virus (HCV) is now recognized as a major cause of liver cirrhosis. This study was aimed at evaluating the natural history of the disease in a large series of Italian patients with HBV- and HCV-related cirrhosis without portal hypertension at entry.
  
  
  METHODS
  The clinical records of 405 patients (233 males, mean age 54 +/- 9 yr) with histologically proven cirrhosis (321 with HCV-related and 84 with HBV-related cirrhosis) and no clinical evidence of portal hypertension at entry were retrospectively examined to evaluate the occurrence of complications and the cumulative mortality rate during follow-up.
  
  
  RESULTS
  Patients had a mean follow-up of 8 +/- 3 yr. The cumulative survival rate was 99.1% at 5 yr, 76.8% at 10 yr, and 49.4% at 15 yr. The age-adjusted death rate was 3.14 and 2.84 times higher than in the general Italian population in men and women, respectively. Only the bilirubin level was an independent indicator of survival. Esophageal varices, ascites, jaundice, hemorrhage, hepatic encephalopathy, and hepatocellular carcinoma significantly reduced the survival rate (major complications), whereas thrombocytopenia, diabetes, and cholelithiasis did not affect survival (minor complications). The incidence of hepatocellular carcinoma was similar in patients with either HBV- or HCV-related disease and was quite frequent, especially in males.
  
  
  CONCLUSIONS
  This study demonstrates that the course of virus-induced liver cirrhosis is not influenced by the etiology of the disease and that the occurrence of complications significantly shortens life expectancy. The longer survival rate observed in this study is probably due to the fact that cirrhosis was here recognized by liver biopsy in the absence of clinical evidence of portal hypertension.
authors.affiliation: Istituto di Medicina Interna, University of Florence, School of Medicine, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Gentilini
authors.forename: G
authors.initials: G
authors.lastname: Laffi
authors.forename: G
authors.initials: G
authors.lastname: La Villa
authors.forename: R G
authors.initials: RG
authors.lastname: Romanelli
authors.forename: G
authors.initials: G
authors.lastname: Buzzelli
authors.forename: V
authors.initials: V
authors.lastname: Casini-Raggi
authors.forename: L
authors.initials: L
authors.lastname: Melani
authors.forename: R
authors.initials: R
authors.lastname: Mazzanti
authors.forename: D
authors.initials: D
authors.lastname: Riccardi
authors.forename: M
authors.initials: M
authors.lastname: Pinzani
authors.forename: A L
authors.initials: AL
authors.lastname: Zignego
mesh_terms: D001663:Bilirubin / Q000097:blood; D006528:Carcinoma, Hepatocellular / Q000150:complications; D002908:Chronic Disease; D004932:Esophageal and Gastric Varices / Q000150:complications; D005260:Female; D005500:Follow-Up Studies; D006471:Gastrointestinal Hemorrhage / Q000150:complications; D006501:Hepatic Encephalopathy / Q000150:complications; D006509:Hepatitis B / Q000150:complications*; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D007565:Jaundice / Q000150:complications; D008103:Liver Cirrhosis / Q000209:etiology* / Q000401:mortality; D008113:Liver Neoplasms / Q000150:complications; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D001663:Bilirubin